公开(公告)号：US09095549B2

公开(公告)日：2015-08-04

申请号：US12097703

申请日：2006-12-15

申请人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

发明人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

IPC分类号： G01N33/53 ,  A61K38/17 ,  G01N33/574

CPC分类号： A61K38/17 ,  G01N33/57419

摘要： The invention relates to a method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being: transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Q15582); suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2); hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7); calponin-2 (SwissProt Acc. No. Q99439); heat shock protein HSP90-beta (SwissProt Acc. No. P08238); phosphoglycerate mutase 1 (SwissProt Acc. No. P18669); serpin C1 protein (SwissProt Acc. No. P01008); or haptoglobin precursor (SwissProt Acc. No. P00738); or a decreased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being serotransferrin (SwissProt Acc. No. P02787); 26S proteasome subunit p40.5 (Swiss Prot Acc. No. Q9UNM7); aldo-keto reductase family 1 member B10 (SwissProt Acc. No. O60218); fructosamine-3-kinase (SwissProt Acc. No. Q9H479); peripherin (SwissProt Acc. No. P41219); alpha-2-macroglobulin (SwissProt Acc. No. P01023); serpin C1 protein (SwissProt Acc. No. P01008); or apolipoprotein A IV (SwissProt Acc. No. P06727). The same proteins can be used for prognosis by detecting changes in their concentration in the course of treatment for colorectal cancer.

摘要翻译： 本发明涉及一种从人体受试者获得的有效身体组织的诊断样本中诊断结肠直肠癌的方法，其包括检测诊断样品中蛋白质浓度的增加，与正常人类样品相比， 蛋白质是：转化生长因子-β诱导的蛋白质IG-H3（SwissProt Acc。No.Q15582）; SKP1同源物（同种型2）（SwissProt Acc。No.Q9Y2Z0-2）的G2等位基因的抑制子; 假定蛋白（URG4的一部分）（SwissProt Acc。No.Q9NWR7）; calponin-2（SwissProt Acc。No.Q99439）; 热休克蛋白HSP90-β（SwissProt Acc。No.P08238）; 磷酸甘油酸变位酶1（SwissProt Acc。编号P18669）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或触珠蛋白前体（SwissProt Acc.P00738）; 或者与正常人样品相比，该蛋白质是血清转铁蛋白（SwissProt Acc.No.P02787）; 26S蛋白酶体亚基p40.5（Swiss Prot Acc。No.Q9UNM7）; 醛醇还原酶家族1成员B10（SwissProt Acc.No.O60218）; 果糖胺-3-激酶（SwissProt Acc。No.Q9H479）; 外周蛋白（SwissProt Acc。No. P41219）; α-2-巨球蛋白（SwissProt Acc.Po1023）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或载脂蛋白A IV（SwissProt Acc.Po6727）。 通过检测结肠直肠癌治疗过程中其浓度的变化可以将相同的蛋白质用于预后。

公开(公告)号：US06342300B1

公开(公告)日：2002-01-29

申请号：US09657326

申请日：2000-09-07

申请人： Holger Bengs ,  Alex Schoenfeld ,  Gitte Boehm ,  Siegfried Weis ,  Joachim Clauss

发明人： Holger Bengs ,  Alex Schoenfeld ,  Gitte Boehm ,  Siegfried Weis ,  Joachim Clauss

IPC分类号： B32B1502

CPC分类号： C08G63/668 ,  C08G63/60 ,  Y10T428/249921 ,  Y10T428/2984 ,  Y10T428/2985 ,  Y10T428/2989

摘要： The invention relates to biodegradable polycondensates, to the production of said polycondensates, and to their use for releasing specific substances. The polycondensates are derived from at least three components chosen from the following group: a) dianhydrohexites b) bivalent (polyvalent) organic carboxylic acids and c) polyvalent organic carboxylic acids which, in addition to two carboxylic acid functions, have at least one other, optionally capped, i.e., OH and/or COOH function.

摘要翻译： 本发明涉及生物降解性缩聚物，所述缩聚物的制备及其用于释放特定物质的用途。 缩聚物衍生自选自以下组的至少三种组分：a）二氢六氯化物b）二价（多价）有机羧酸和c）多价有机羧酸，除了两个羧酸官能团之外，还有至少一种其它羧酸， 可选地封端，即OH和/或COOH官能团。

公开(公告)号：US20090226905A1

公开(公告)日：2009-09-10

申请号：US12097703

申请日：2006-12-15

申请人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

发明人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

IPC分类号： G01N33/53 ,  C12Q1/68

CPC分类号： A61K38/17 ,  G01N33/57419

摘要： The invention relates to a method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being: transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Q15582); suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2); hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7); calponin-2 (SwissProt Acc. No. Q99439); heat shock protein HSP90-beta (SwissProt Acc. No. P08238); phosphoglycerate mutase 1 (SwissProt Acc. No. P18669); serpin Cl protein (SwissProt Acc. No. P01008); or haptoglobin precursor (SwissProt Acc. No. P00738); or a decreased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being serotransferrin (SwissProt Acc. No. P02787); 26S proteasome subunit p40.5 (Swiss Prot Acc. No. Q9UNM7); aldo-keto reductase family 1 member B10 (SwissProt Acc. No. O60218); fructosamine-3-kinase (SwissProt Acc. No. Q9H479); peripherin (SwissProt Acc. No. P41219); alpha-2-macroglobulin (SwissProt Acc. No. P01023); serpin C1 protein (SwissProt Acc. No. P01008); or apolipoprotein A IV (SwissProt Acc. No. P06727). The same proteins can be used for prognosis by detecting changes in their concentration in the course of treatment for colorectal cancer.

摘要翻译： 本发明涉及一种从人体受试者获得的有效身体组织的诊断样本中诊断结肠直肠癌的方法，其包括检测诊断样品中蛋白质浓度的增加，与正常人类样品相比， 蛋白质是：转化生长因子-β诱导的蛋白质IG-H3（SwissProt Acc。No.Q15582）; SKP1同源物（同种型2）（SwissProt Acc。No.Q9Y2Z0-2）的G2等位基因的抑制子; 假定蛋白（URG4的一部分）（SwissProt Acc。No.Q9NWR7）; calponin-2（SwissProt Acc。No.Q99439）; 热休克蛋白HSP90-β（SwissProt Acc。No.P08238）; 磷酸甘油酸变位酶1（SwissProt Acc。编号P18669）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或触珠蛋白前体（SwissProt Acc.P00738）; 或者与正常人样品相比，该蛋白质是血清转铁蛋白（SwissProt Acc.No.P02787）; 26S蛋白酶体亚基p40.5（Swiss Prot Acc。No.Q9UNM7）; 醛醇还原酶家族1成员B10（SwissProt Acc.No.O60218）; 果糖胺-3-激酶（SwissProt Acc。No.Q9H479）; 外周蛋白（SwissProt Acc。No. P41219）; α-2-巨球蛋白（SwissProt Acc.Po1023）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或载脂蛋白A IV（SwissProt Acc.Po6727）。 通过检测结肠直肠癌治疗过程中其浓度的变化可以将相同的蛋白质用于预后。